|1.||Goldhirsch, Aron: 24 articles (12/2015 - 12/2005)|
|2.||Goss, Paul E: 24 articles (04/2014 - 06/2002)|
|3.||Dixon, J Michael: 21 articles (07/2015 - 06/2002)|
|4.||Evans, Dean B: 21 articles (02/2012 - 10/2003)|
|5.||Price, Karen N: 20 articles (12/2015 - 12/2005)|
|6.||Gelber, Richard D: 20 articles (12/2015 - 12/2005)|
|7.||Thürlimann, Beat: 19 articles (12/2015 - 12/2005)|
|8.||Brodie, Angela: 19 articles (11/2015 - 03/2002)|
|9.||Perez, Edith A: 18 articles (08/2015 - 11/2003)|
|10.||Coates, Alan S: 17 articles (12/2015 - 12/2005)|
|1.||Breast Neoplasms (Breast Cancer)
04/01/2004 - "[Complete remission obtained with letrozole in a man with metastatic breast cancer]."
01/01/2015 - "The addition of palbociclib to letrozole in this phase 2 study significantly improved progression-free survival in women with advanced oestrogen receptor-positive and HER2-negative breast cancer. "
03/16/2010 - "We found that letrozole and ZA induce levels of apoptosis in breast cancer cells in vitro that are significantly greater compared with treatment with each drug alone. "
08/01/2007 - "In MA.17 at 30 months, postmenopausal patients with early stage breast cancer who received extended adjuvant letrozole (n = 2593) experienced a significant (42%) improvement in DFS regardless of nodal status (P < 0.001), and there was a significant (39%) improvement in as in node-positive patients (P = 0.04), compared with placebo. "
01/01/2007 - "At a median follow-up of 30 months, letrozole significantly improved disease-free survival (DFS; P<0.001), the primary end point, compared with placebo (hazard ratio [HR] for recurrence or contralateral breast cancer 0.58; 95% confidence interval [CI] 0.45, 0.76] P<0.001). "
03/01/2011 - "ENT plus letrozole also prevented lung colonization and growth of tumor cells, with a significant reduction (P > 0.03) in both visible and microscopic foci. "
01/01/2007 - "Furthermore, letrozole significantly improved distant DFS (HR=0.60; 95% CI 0.43, 0.84; P=0.002) and, in women with node-positive tumors, overall survival (HR=0.61; 95% CI 0.38, 0.98; P=0.04). "
01/01/2005 - "Disease-free survival was significantly improved with letrozole vs placebo, irrespective of whether patients had lymph node-positive or node-negative tumors. "
04/01/2014 - "The results from this trial suggest that extended letrozole therapy in the neoadjuvant setting (7.5 months), as opposed to conventional treatment of 4 months, is optimal to achieve maximum reduction in tumor volume sufficient for BCS."
06/15/2008 - "In the current study, we evaluated the effect of discontinuing letrozole treatment on the growth of letrozole-resistant cells and tumors. "
|3.||Neoplasm Metastasis (Metastasis)
10/01/2009 - "Letrozole also significantly reduces the occurrence of early distant metastases, the most lethal type of recurrence event, which can lead to improved survival. "
12/01/2008 - "Extended adjuvant letrozole reduced the risk of recurrence by 42% and the risk of distant metastases by 40%, it was well tolerated compared to placebo; among lymph node-positive patients, overall survival was significantly improved. "
09/01/2007 - "Subsequent analyses confirmed that letrozole significantly reduced recurrences, including distant metastases, and, in patients with node-positive disease, the agent also significantly improved overall survival, with the benefit of letrozole increasing with duration of therapy, at least up to 48 months. "
11/01/2012 - "Multiple bone metastases were detected 18 months after the surgery during treatment with letrozole as adjuvant therapy. "
03/01/2011 - "After careful examination, the patient was diagnosed as having multiple bone metastases and her medication was changed to oral letrozole. "
11/01/2006 - "Mean change in QOL scores for minority women who received letrozole demonstrated improved mental health at the 6-month assessment (P = 0.02) and less bodily pain at the 12-month assessment (P = 0.046). "
10/01/2005 - "On the response analysis, a significant difference was seen between groups for the bodily pain domain (percentage of patients reporting a worsening of QOL, 47% placebo v 51% letrozole; P = .009) and the vasomotor domain (22% placebo v 29% letrozole; P = .001). "
01/01/2011 - "Letrozole given with combined pills achieved complete regression of recurrent endometriotic cysts and pain relief in all cases."
01/01/2014 - "To determine the role of Letrozole, an aromatase inhibitor, in the treatment of endometriotic pain. "
07/01/2007 - "Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging."
|5.||Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
09/01/2015 - "A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice."
02/01/2014 - "Letrozole stimulation in endometrial preparation for cryopreserved-thawed embryo transfer in women with polycystic ovarian syndrome: a pilot study."
08/01/2012 - "Two groups of experimental polycystic ovary syndrome model were composed in healthy female rats by per oral letrozole administration of for 21 and 42 days. "
04/01/2012 - "formulation restores lipid profile to normal in a letrozole-induced polycystic ovarian syndrome rat model."
10/01/2010 - "formulation on Letrozole induced polycystic ovarian syndrome rat model."
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)